Arthur M. Cohen & Associates’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $21.2M | Sell |
22,166
-321
| -1% | -$325K | 3.76% | 9 |
|
|
2025
Q4 | $24.2M | Sell |
22,487
-359
| -2% | -$343K | 3.95% | 10 |
|
|
2025
Q3 | $17.4M | Buy |
22,846
+120
| +0.5% | +$89.3K | 2.93% | 10 |
|
|
2025
Q2 | $17.7M | Sell |
22,726
-875
| -4% | -$680K | 3.13% | 10 |
|
|
2025
Q1 | $19.5M | Sell |
23,601
-581
| -2% | -$483K | 3.74% | 10 |
|
|
2024
Q4 | $18.7M | Sell |
24,182
-1,291
| -5% | -$1.07M | 3.31% | 10 |
|
|
2024
Q3 | $22.5M | Sell |
25,473
-307
| -1% | -$276K | 4.07% | 10 |
|
|
2024
Q2 | $23.3M | Sell |
25,780
-225
| -0.9% | -$180K | 4.28% | 10 |
|
|
2024
Q1 | $20.3M | Sell |
26,005
-848
| -3% | -$603K | 4.29% | 9 |
|
|
2023
Q4 | $15.7M | Sell |
26,853
-2,309
| -8% | -$1.35M | 3.68% | 8 |
|
|
2023
Q3 | $15.7M | Sell |
29,162
-1,081
| -4% | -$557K | 4.01% | 8 |
|
|
2023
Q2 | $14.2M | Sell |
30,243
-929
| -3% | -$390K | 3.52% | 8 |
|
|
2023
Q1 | $10.7M | Sell |
31,172
-2,349
| -7% | -$792K | 2.87% | 8 |
|
|
2022
Q4 | $12.3M | Sell |
33,521
-4,246
| -11% | -$1.51M | 3.35% | 8 |
|
|
2022
Q3 | $12.2M | Sell |
37,767
-1,562
| -4% | -$495K | 3.36% | 8 |
|
|
2022
Q2 | $12.9M | Sell |
39,329
-715
| -2% | -$215K | 3.21% | 9 |
|
|
2022
Q1 | $11.5M | Sell |
40,044
-5,436
| -12% | -$1.4M | 2.42% | 9 |
|
|
2021
Q4 | $12.6M | Sell |
45,480
-1,275
| -3% | -$323K | 2.33% | 10 |
|
|
2021
Q3 | $10.8M | Sell |
46,755
-247
| -0.5% | -$61K | 2.19% | 10 |
|
|
2021
Q2 | $10.8M | Buy |
47,002
+20,379
| +77% | +$4.09M | 2.09% | 12 |
|
|
2021
Q1 | $8.75M | Sell |
26,623
-20,047
| -43% | -$3.92M | 2.02% | 12 |
|
|
2020
Q4 | $7.88M | Hold |
46,670
| – | – | 1.85% | 12 |
|
|
2020
Q3 | $6.91M | Buy |
46,670
+640
| +1% | +$99.1K | 1.79% | 12 |
|
|
2020
Q2 | $7.91M | Hold |
46,030
| – | – | 2.38% | 10 |
|
|
2020
Q1 | $6.28M | Sell |
46,030
-320
| -0.7% | -$44K | 2.49% | 10 |
|
|
2019
Q4 | $6.09M | Sell |
46,350
-1,830
| -4% | -$212K | 1.87% | 14 |
|
|
2019
Q3 | $5.39K | Buy |
48,180
+1,307
| +3% | +$146K | 1.52% | 16 |
|
|
2019
Q2 | $5.27M | Sell |
46,873
-2,170
| -4% | -$256K | 1.8% | 14 |
|
|
2019
Q1 | $6.36M | Sell |
49,043
-320
| -0.6% | -$38.9K | 2.27% | 12 |
|
|
2018
Q4 | $5.71K | Buy |
49,363
+45
| +0.1% | +$5.03K | 1.82% | 13 |
|
|
2018
Q3 | $5.29K | Sell |
49,318
-5
| -0% | -$500 | 1.61% | 14 |
|
|
2018
Q2 | $4.21M | Sell |
49,323
-175
| -0.4% | -$14.4K | 1.59% | 15 |
|
|
2018
Q1 | $3.78M | Buy |
49,498
+135
| +0.3% | +$10.9K | 1.43% | 16 |
|
|
2017
Q4 | $5.71K | Buy |
+49,363
| New | +$4.2M | 1.57% | 13 |
|
|
2017
Q2 | $3.94M | Sell |
5,471
-47,726
| -90% | -$3.89M | 1.54% | 17 |
|
|
2017
Q1 | $3.92M | Buy |
53,197
+5,820
| +12% | +$466K | 1.75% | 15 |
|
|
2016
Q4 | $3.48M | Buy |
+47,377
| New | +$3.53M | 1.84% | 12 |
|
|
2014
Q3 | $4.11M | Buy |
+48,040
| New | +$3.04M | 1.91% | 12 |
|
Other funds holding LLY
VCM
VPM
Arthur M. Cohen & Associates's LLY Position: Q1 2026 in Review
Arthur M. Cohen & Associates reduced its Eli Lilly (LLY) stake by 1.4% in Q1 2026, selling an estimated $325K and leaving 22,166 shares worth $21.2M. The position accounts for 3.76% of the portfolio, ranked #9.
Arthur M. Cohen & Associates first reported a position in LLY in Q3 2014 and has held it in 38 quarters since. The position peaked at $24.2M in Q4 2025. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Arthur M. Cohen & Associates held 22,166 shares of Eli Lilly worth $21.2M as of Q1 2026.
- Arthur M. Cohen & Associates sold 321 Eli Lilly shares in Q1 2026, an estimated $325K.
- Eli Lilly made up 3.76% of Arthur M. Cohen & Associates's portfolio in Q1 2026, its #9 holding.
- Arthur M. Cohen & Associates first reported a position in Eli Lilly in Q3 2014 and has held it in 38 quarters since.
- Arthur M. Cohen & Associates's Eli Lilly position peaked at $24.2M in Q4 2025.
- 4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Arthur M. Cohen & Associates's 13F filing for Q1 2026, filed 8 May 2026.